A package of capsules Common adverse drug reactions (ADRs) associated with<unk>  therapy (occurring in over 1 percent of people) include nausea and vomiting. In adults,<unk>  increased the risk of nausea for which the number needed to harm was 28 and for vomiting was 22. So, for every 22 adult people on<unk>  one experienced vomiting. In the treatment of children,<unk>  also induced vomiting. The number needed to harm was 19. So, for every 19 children on<unk>  one experienced vomiting. In prevention there were more headaches, kidney, and psychiatric events.<unk> 's effect on the heart is unclear: it may reduce cardiac symptoms, but may also induce serious arrhythmias. Postmarketing reports include liver inflammation and elevated liver enzymes, rash, allergic reactions including anaphylaxis, toxic epidermal necrolysis, abnormal heart rhythms, seizure, confusion, aggravation of diabetes, and haemorrhagic colitis and Stevens–Johnson syndrome. The US and EU package inserts for<unk>  contain a warning of psychiatric effects observed in post-marketing surveillance. The frequency of these appears to be low and a causative role for<unk>  has not been established. The 2014 Cochrane Review found a dose-response effect on psychiatric events. In trials of prevention in adults one person was harmed for every 94 treated. Neither of the two most cited published treatment trials of<unk>  reported any drug-attributable serious adverse events. It is pregnancy category C in the United States and category B in Australia, meaning that it has been taken by a small number of women without signs of problems and in animal studies it looks safe. Dose adjustment may be needed in those with kidney problems.
Oseltamivir
Zanamivir
Peramivir
Valaciclovir
Umifenovir
Quifenadine
Faricimab
Rimantadine